AbbVie Inc. (NYSE:ABBV) is making headlines as Tom Lee reiterates a bullish market outlook amid AI catalysts. Jim Lebenthal of Cerity Partners likes AbbVie for its attractive valuation and dividend yield. ABBV shares have surged 27% this year. However, Carillon Eagle Growth & Income Fund noted a weakness in ABBV shares in the second quarter due to industry underperformance and policy threats. While ABBV has potential, some AI stocks may offer higher returns with limited downside risk. For more insights, check out the best short-term AI stock report. Stay informed with 30 stocks that could double in 3 years and 11 hidden AI stocks to buy now.

Read more at Yahoo Finance: Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation